These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25343064)

  • 1. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 Feb; 1(1):3-9. PubMed ID: 25343064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intractable and rare diseases research in Asia.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drugs: the regulatory environment.
    Franco P
    Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan drug development: The impact of regulatory and reimbursement frameworks.
    Huang YJ; Chao WY; Wang CC; Chang LC
    Drug Discov Today; 2022 Jun; 27(6):1724-1732. PubMed ID: 35257859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea.
    Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH
    J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare disease patients in China anticipate the sunlight of legislation.
    Gao JJ; Song PP; Tang W
    Drug Discov Ther; 2013 Jun; 7(3):126-8. PubMed ID: 23917862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New opportunity for orphan drug development in Japan: Early exploratory clinical trial bases promote drug translation from basic studies to clinical application.
    Song P; Gao J; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 May; 1(2):95-7. PubMed ID: 25343079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current progress in the management of rare diseases and orphan drugs in China.
    Gong S; Jin S
    Intractable Rare Dis Res; 2012 May; 1(2):45-52. PubMed ID: 25343073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America.
    Arnold RJ; Bighash L; Bryón Nieto A; Tannus Branco de Araújo G; Gay-Molina JG; Augustovski F
    F1000Res; 2015; 4():57. PubMed ID: 25844162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.